Pulmonary Rehabilitation Outcomes of Post-Acute COVID-19 Patients during Different Waves of the Pandemic

Author:

Spielmanns Marc12ORCID,Schaer Corina E.1ORCID,Pekacka-Egli Anna-Maria1,Spielmanns Sabine1,Ibish Olberk1,Gafina Guzel1,Stiube Antonela1,Hermann Matthias3ORCID

Affiliation:

1. Pulmonary Medicine, Zuercher RehaZentren, Klinik Wald, 8636 Wald, Switzerland

2. Department for Pulmonary Medicine, Faculty of Health, University Witten Herdecke, 58455 Witten, Germany

3. Department of Cardiology, University Heart Center, University Hospital Zurich, 8006 Zurich, Switzerland

Abstract

(1) Background: Between the beginning of the coronavirus pandemic and summer 2022, we distinguished four pandemic waves, with different characteristics of the affected patients. This study investigated the impact of patient characteristics on the outcome of inpatient pulmonary rehabilitation (PR). (2) Methods: Using a prospective approach, the characteristics of post-acute COVID-19 patients of the different waves who participated in inpatient PR were compared based on their assessments and results collected as part of PR (Cumulative Illness Rating Scale (CIRS), six-minute walk test (6-MWT), Pulmonary Function Testing (PFT), and Functional Independent Measurement (FIM). (3) Results: A total of 483 patients were included in the analysis (Wave 1 n = 51, Wave 2 n = 202, Wave 3 n = 84, Wave 4 n = 146). Compared to Wave 3 + 4, patients of Wave 1 + 2 were older (69 vs. 63 years; p < 0.001), had a significantly lower CIRS (13.0 vs. 14.7 points; p = 0.004), had significant better PFT (FVC: 73 vs. 68%pred; p = 0.009; DLCOSB: 58 ± 18 vs. 50 ± 17%pred; p = 0.001), and showed significantly more comorbidities (2.0 vs. 1.6 n/pers.; p = 0.009). Wave 3 + 4 showed significantly greater improvements according to the 6-MWT (147 vs. 188 m; p < 0.001) and the FIM (5.6 vs. 21.1 points; p < 0.001). (4) Conclusions: Patients of the COVID-19 infection waves differed significantly according to their anthropometric data, incidence of comorbidities, and impact of the infection. All cohorts achieved clinically relevant and significant functional improvements during PR, with significant higher improvements in Wave 3 + 4.

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference32 articles.

1. (2022, December 28). Pneumonia of Unknown Cause–China. Available online: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229.

2. (2022, December 28). Entwicklung der Coronavirus-Epidemie (COVID-19) in der Schweiz seit Februar 2020. Available online: https://de.statista.com/statistik/daten/studie/1101371/umfrage/entwicklung-der-fallzahlen-des-coronavirus-in-der-schweiz/.

3. COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS;Gibson;Med. J. Aust.,2020

4. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study;Zhou;Lancet,2020

5. Silverio, A., Di Maio, M., Citro, R., Esposito, L., Iuliano, G., Bellino, M., Baldi, C., De Luca, G., Ciccarelli, M., and Vecchione, C. (2021). Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: Systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc. Disord., 21.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3